Relieves osteoarthritis and rheumatoid arthritis. ANDA 219118, held by Novitium Pharma. Nabumetone.
As of Nov 15, 2026, ANDA 219118 (Nabumetone), held by Novitium Pharma, was first approved by FDA on Jan 7, 2025, with 0 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Carefully consider the potential benefits and risks of nabumetone tablets, USP and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Nabumetone tablets, USP are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 7, 2025 | Original application | Approved | None posted |
| Nabumetone500MG · tablet;oral | Nabumetone | Rx |
| Nabumetone750MG · tablet;oral | Nabumetone | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters